EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Interleukin‐2‐induced skin inflammation

Charline Sommer iD, Jarish N Cohen, Susann Dehmel iD, Vanessa Neuhaus iD, Dirk Schaudien iD, Armin Braun, Katherina Sewald iD, Michael D Rosenblum

European Journal of Immunology · 2024

DOI: 10.1002/eji.202350580 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Immunology, 2024. Verfasst von Charline Sommer und 7 weiteren Autor:innen. Beteiligte Einrichtung: Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), M…. Hauptthemen laut MEDLINE: Interleukin-2, Immunity, Innate. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, NIH HHS, NIAMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recombinant human IL‐2 has been used to treat inflammatory diseases and cancer; however, side effects like skin rashes limit the use of this therapeutic. To identify key molecules and cells inducing this side effect, we characterized IL‐2‐induced cutaneous immune reactions and investigated the relevance of CD25 (IL‐2 receptor α) in the process. We injected IL‐2 intradermally into WT mice and observed increases in immune cell subsets in the skin with preferential increases in frequencies of IL‐4‐ and IL‐13‐producing group 2 innate lymphoid cells and IL‐17‐producing dermal γδ T cells. This overall led to a shift toward type 2/type 17 immune responses. In addition, using a novel topical genetic deletion approach, we reduced CD25 on skin, specifically on all cutaneous cells, and found that IL‐2‐dependent effects were reduced, hinting that CD25 — at least partly — induces this skin inflammation. Reduction of CD25 specifically on skin Tregs further augmented IL‐2‐induced immune cell infiltration, hinting that CD25 on skin Tregs is crucial to restrain IL‐2‐induced inflammation. Overall, our data support that innate lymphoid immune cells are key cells inducing side effects during IL‐2 therapy and underline the significance of CD25 in this process.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-2Immunity, InnateMiceHumansAnimalsLymphocytesInflammationT-Lymphocytes, RegulatoryInterleukin-2 Receptor alpha SubunitSkin

Stichwörter der Autor:innen

Drug‐induced skin inflammationIL‐2 therapyImmunotherapyInnate lymphoid cellsγδ T cells

Substanzen

Interleukin-2Interleukin-2 Receptor alpha Subunit

Autor:innen und Institutionen

  • Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Member of the German Center for Lung Research (DZL), Member of the Frau…
  • Department of Dermatology, University of California, San Francisco, California, USA.
  • Department of Pathology, University of California, San Francisco, California, USA.
  • Institute of Immunology, Hannover Medical School, Hannover, Germany.

ORCID-Profile: Charline Sommer, Susann Dehmel, Vanessa Neuhaus, Dirk Schaudien, Katherina Sewald

Förderung

  • NIDDK NIH HHS
  • NIH HHS
  • NIAMS NIH HHS

Zitieren

APA

Sommer, C., Cohen, J. N., Dehmel, S., Neuhaus, V., Schaudien, D., Braun, A., Sewald, K., & Rosenblum, M. D. (2024). Interleukin‐2‐induced skin inflammation. European Journal of Immunology. https://doi.org/10.1002/eji.202350580

Vancouver

Sommer C, Cohen JN, Dehmel S, Neuhaus V, Schaudien D, Braun A, et al. Interleukin‐2‐induced skin inflammation. European Journal of Immunology. 2024. doi:10.1002/eji.202350580

BibTeX
@article{Sommer2024,
  author = {Sommer, Charline and Cohen, Jarish N and Dehmel, Susann and Neuhaus, Vanessa and Schaudien, Dirk and Braun, Armin and Sewald, Katherina and Rosenblum, Michael D},
  title = {Interleukin‐2‐induced skin inflammation},
  journal = {European Journal of Immunology},
  year = {2024},
  doi = {10.1002/eji.202350580}
}
Kostenlos starten →